Table 1.

Patient characteristics

Patient	Age/Sex	Primary disease	Hx acute skin GvHD	Hx chronic skin GvHD	cGvHD of other organ systems	Voriconazole dose	Latency between voriconazole initiation and phototoxicity	Concurrent potentially photosensitizing drugs	cGVHD therapy at time of phototoxicity diagnosis	Resolution of phototoxicity
1	15/M	Alveolar rhabdomyosarcoma	Yes	Yes	Oral	200mg BID	2 weeks	None	Prednisone 8mg QD	3 weeks
2	6/F	Pre-B cell ALL	Yes	Yes	None	175mg BID	6 months	HCTZ	Prednisone 25mg BID Tacrolimus 0.5mg QAM, 0.25 QPM MMF 750mg q12hr Hydrocortisone 2.5% BID (face) Fluocinolone 0.1% BID (body)	2 weeks
3	40/F	Large B-cell lymphoma	Yes	Yes	Ocular Oral Hepatic	200mg BID	42 months	Amitriptyline	Extracorporeal photopheresis Prednisone 40mg QD Fluocinolone solution (scalp) Clobetasol ointment 0.05% (body) Tacrolimus ointment (face)	Improved in3 days, continued cGvHD flare
4	47/M	CML	Yes	Yes	Ocular Hepatic Pulmonary	200mg BID	1 month	None	Prednisone 50mg QOD MMF 1gm q12hr	4 months
5	59/M	Myeloid metaplasia/myelofibrosis	No	No	Ocular Hepatic Pulmonary	200mg BID	3 months	Lisinopril Furosemide	Prednisone 20mg QOD	3 months

Abbreviations: ALL, acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; HCTZ, hydrochlorothiazide; MMF, mycophenolate mofetil